Abstract: Objective To evaluate the clinical efficacy and safety of bevacizumab plus radiochemotherapy in treatment of locally advanced head and neck squamous carcinoma. Methods A total of 40 patients with locally advanced squamous carcinoma recruited from October 2014 to October 2015 in Chinese PLAgeneral Hospital were randomly divided into two groups.Twenty patients in experimental group (bevacizumab group) received bevacizumab + 2 cycles of docetaxel combined with cisplatin induction chemotherapy, following bevacizumab plus concomitant radiochemotherapy, and the other 20 patients in control group received same regimen as above but without bevacizumab. All patients in two groups underwent helical tomotherapy. Results The objective response rates in experimental group and control group were 100% (20/20) and 80% (16/20) after 3 months of therapy with significant difference (P=0.000 2). In addition to lymphocyte reduction, most of acute toxicity was graded as 1 to 2 degree, with no significant difference between experimental group and control group (P ＞ 0.05). Conclusion Bevacizumab combined with chemoradiotherapy is safe and effective in locally advanced head and neck squamous cell carcinoma.